As the global pharma industry experiences turbulence from the heightened geopolitical tensions between the US and China, former and incumbent regulatory officials from China and the European Union tried to inject the sector with reassurances of collaboration on innovation and access at the recent DIA China Annual Meeting.
From the China side, however, messages meant to offer relief may have come across as less than confident. In a...








